Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor

被引：0
|
作者：
Dorien Groenendaal-van de Meent
Martin den Adel
Jan Noukens
Sanne Rijnders
Axel Krebs-Brown
Lyudmila Mateva
Assen Alexiev
Marloes Schaddelee
机构：
[1] Astellas Pharma Europe B.V.,Gastroenterology Clinic
[2] Kinesis Pharma B.V.,Business Development, Transaction Execution Group
[3] University Hospital St Ivan Rilski,undefined
[4] Medical University–Sofia,undefined
[5] COMAC Medical Ltd,undefined
[6] Astellas Pharma Inc.,undefined
来源：
Clinical Drug Investigation | 2016年 / 36卷
关键词：
Chronic Kidney Disease; Hepatic Impairment; Moderate Hepatic Impairment; Normal Hepatic Function; Impaired Hepatic Function;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：743 / 751
页数：8
相关论文
共 50 条
  • [1] Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor
    Groenendaal-van de Meent, Dorien
    den Adel, Martin
    Noukens, Jan
    Rijnders, Sanne
    Krebs-Brown, Axel
    Mateva, Lyudmila
    Alexiev, Assen
    Schaddelee, Marloes
    CLINICAL DRUG INVESTIGATION, 2016, 36 (09) : 743 - 751
  • [2] Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor
    Chavan, Ajit
    Burke, Leontia
    Sawant, Rishikesh
    Navarro-Gonzales, Pamela
    Vargo, Dennis
    Paulson, Susan K.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (08): : 950 - 958
  • [3] Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor
    Groenendaal-van de Meent, Dorien
    Kerbusch, Virginie
    Kaspera, Rudiger
    Barroso-Fernandez, Begona
    Galletti, Piergiorgio
    Klein, Gernot K.
    den Adel, Martin
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2021, 46 (01) : 141 - 153
  • [4] Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor
    Dorien Groenendaal-van de Meent
    Virginie Kerbusch
    Rudiger Kaspera
    Begona Barroso-Fernandez
    Piergiorgio Galletti
    Gernot K. Klein
    Martin den Adel
    European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46 : 141 - 153
  • [5] MODERATE HEPATIC IMPAIRMENT HAS ONLY A MINOR IMPACT ON THE PHARMACOKINETICS OF ROXADUSTAT, AN ORAL HYPOXIA-INDUCIBLE FACTOR PROLYL-HYDROXYLASE INHIBITOR
    Groenendaal-van de Meent, Dorien
    den Adel, Martin
    Noukens, Jan
    Rijnders, Sanne
    Krebs-Brown, Axel
    Mateva, Lyudmila
    Alexiev, Assen
    Schaddelee, Marloes
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [6] EFFECT OF SEVERE RENAL IMPAIRMENT OR END-STAGE RENAL DISEASE ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF ROXADUSTAT, AN ORAL HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR
    Groenendaal-van de Meent, Dorien
    Kerbusch, Virginie
    Kaspera, Rudiger
    Barroso-Fernandez, Begona
    Galletti, Piergiorgio
    Klein, Gernot K.
    Den Adel, Martin
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 58 - 58
  • [7] ROXADUSTAT Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor Treatment of Anemia
    Virgili-Lopez, G.
    DRUGS OF THE FUTURE, 2014, 39 (11) : 783 - 791
  • [8] HYPOXIA-INDUCIBLE PROLYL HYDROXYLASE INHIBITOR (ROXADUSTAT) SUPPRESSES KIDNEY STONE FORMATION
    Kawase, Kengo
    Hamamoto, Shuzo
    Hattori, Tatsuya
    Chaya, Ryosuke
    Okada, Tomoki
    Tanaka, Yutaro
    Sugino, Takeru
    Unnno, Rei
    Taguchi, Kazumi
    Ando, Ryosuke
    Okada, Atsushi
    Yasui, Takahiro
    Yasui, Takahiro
    JOURNAL OF UROLOGY, 2022, 207 (05): : E68 - E68
  • [9] Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD
    Provenzano, Robert
    Besarab, Anatole
    Sun, Chao H.
    Diamond, Susan A.
    Durham, John H.
    Cangiano, Jose L.
    Aiello, Joseph R.
    Novak, James E.
    Lee, Tyson
    Leong, Robert
    Roberts, Brian K.
    Saikali, Khalil G.
    Hemmerich, Stefan
    Szczech, Lynda A.
    Yu, Kin-Hung Peony
    Neff, Thomas B.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2016, 11 (06): : 982 - 991
  • [10] A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat
    Yan, Zhipeng
    Xu, Gaosi
    FRONTIERS IN MEDICINE, 2020, 7
12345